Koninklijke Philips (NYSE:PHG – Get Free Report) has been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $28.20.
A number of equities research analysts have recently issued reports on the company. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, October 21st. The Goldman Sachs Group started coverage on shares of Koninklijke Philips in a research report on Wednesday, July 12th. They issued a “buy” rating for the company. Citigroup upped their target price on shares of Koninklijke Philips to €19.00 ($20.21) in a report on Friday, July 7th. Finally, TheStreet upgraded Koninklijke Philips from a “d+” rating to a “c-” rating in a report on Monday, July 24th.
Read Our Latest Research Report on PHG
Institutional Inflows and Outflows
Koninklijke Philips Price Performance
NYSE:PHG opened at $18.61 on Tuesday. The stock’s 50-day simple moving average is $20.32 and its 200 day simple moving average is $20.54. Koninklijke Philips has a 52-week low of $11.75 and a 52-week high of $23.30. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.69 and a current ratio of 1.20. The company has a market cap of $17.28 billion, a P/E ratio of -25.49 and a beta of 0.93.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services.
Further Reading
- Five stocks we like better than Koninklijke Philips
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Amazon just gave us 3 reasons to expect fresh highs
- How to Invest in the Entertainment Industry
- McDonald’s bottoms, plus more good news for fast food stocks
- How is Compound Interest Calculated?
- Is Apple a buy ahead of earnings?
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.